Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer

Journal of Translational Medicine

Robert B Darnell¹  Dana E Orange⁴  Nathalie E Blachère³  Salina Parveen²  Julia Kaufman²  Mayu O Frank² 

[1]New York Genome Center, 101 Avenue of the Americas, New York 10013, NY, USA

[2]Laboratory of Molecular Neuro-oncology, The Rockefeller University, 1230 York Avenue, New York 10065, NY, USA

[3]Howard Hughes Medical Institute, Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York 10065, NY, USA

[4]Hospital for Special Surgery, 535 East 70th Street, New York 10021, NY, USA

关键词: Adjuvant;    Cancer;    Immunogenicity;    Lymphocytes;    Vaccine;    Dendritic cells;   

Others  :  1146899
DOI  :  10.1186/s12967-014-0338-3

 received in 2014-09-29, accepted in 2014-11-21,  发布年份 2014

【 摘 要 】

Background

Dendritic cells are currently under investigation for their ability to generate anti-cancer immune responses. No consensus has been reached as to the optimal method of dendritic cell vaccine preparation and is a barrier to success in the field.

Methods

Over a course of three separate dendritic cell vaccine studies to treat cancer, we tested two different methods for preparing dendritic cells from peripheral blood mononuclear cells: adherence and antibody-selected CD14+ cells.

Results

Surprisingly, we found that patients who received dendritic cell vaccines generated by the adherence method mounted increased T cell proliferation in response to vaccination. This difference could not be accounted for by dendritic cell vaccine dose, cell surface phenotype or dendritic cell function in vitro. One notable difference between the two vaccine preparation methods was that the dendritic cell vaccine cultures generated by the adherence method contained up to 10% lymphocytes, and these lymphocytes were proliferating and producing IFNγ in response to antigen in vitro at the time of administration.

Conclusions

Enhanced immunogenicity of adherence dendritic cell vaccinations may be due to the presence of lymphocytes during dendritic cell culture.

Trial registration

Clinicaltrials.gov identifiers: NCT00289341 webcite, NCT00345293 webcite, and NCT00893945 webcite

【 授权许可】

   
2014 Frank et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Ingulli E, Mondino A, Khoruts A, Jenkins MK: In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med 1997, 185:2133-2141.
• [2]Mehta-Damani A, Markowicz S, Engleman EG: Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 1994, 153:996-1003.
• [3]Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179:1109-1118.
• [4]Zhou LJ, Tedder TF: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A 1996, 93:2588-2592.
• [5]Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27:3135-3142.
• [6]Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998, 4:1321-1324.
• [7]Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
• [8]Darnell RB: Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A 1996, 93:4529-4536.
• [9]Bevan MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976, 143:1283-1288.
• [10]Carbone FR, Bevan MJ: Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990, 171:377-387.
• [11]Frank MO, Kaufman J, Tian S, Suarez-Farinas M, Parveen S, Blachere NE, Morris MJ, Slovin S, Scher HI, Albert ML, Darnell RB: Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One 2010, 5(9):e12367. doi:10.1371/journal.pone.0012367
• [12]Orange DE, Jegathesan M, Blachere NE, Frank MO, Scher HI, Albert ML, Darnell RB: Effective antigen cross-presentation by prostate cancer patients’ dendritic cells: implications for prostate cancer immunotherapy. Prostate Cancer Prostatic Dis 2004, 7:63-72.
• [13]Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997, 186:2075-2080.
• [14]Berk E, Kalinski P: Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs. Oncoimmunology 2012, 1:1443-1444.
• [15]Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P: CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003, 63:2836-2843.
• [16]Kretschmer B, Kuhl S, Fleischer B, Breloer M: Activated T cells induce rapid CD83 expression on B cells by engagement of CD40. Immunol Lett 2011, 136:221-227.
• [17]Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Moretti A, Migliori G, Fiorentini G: Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004, 2:27. BioMed Central Full Text
• [18]Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN: Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006, 440:890-895.
• [19]Butterfield LH: Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol 2013, 4:454.
• [20]Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 2014, 63:407-418.
• [21]Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I: Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol 2014, 27:89-97.
• [22]Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18:3894-3903.